Beovu Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The beovu market research report is one of a series of new reports that provides beovu market statistics, including beovu industry global market size, regional shares, competitors with a beovu market share, detailed beovu market segments, market trends and opportunities, and any further data you may need to thrive in the beovu industry. This beovu market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to rising prevalence of age-related macular degeneration, increasing demand for targeted therapies, potential for longer-lasting treatment options, expanding reimbursement policies, and growing investment in retinal disease research and clinical trials. Major trends in the forecast period include advancements in ophthalmic treatment technologies, development of gene therapy options, integration of AI in treatment planning, shift toward preventive eye care, and advancement of sustained-release drug delivery systems.

The increasing prevalence of retinal diseases is expected to drive the growth of the beovu market in the future. Retinal diseases refer to conditions that affect the retina, the light-sensitive tissue at the back of the eye, including age-related macular degeneration (AMD), diabetic retinopathy, retinal detachment, and macular edema. These conditions often result in vision impairment. The rise in retinal diseases is driven by factors such as aging populations, a growing number of diabetes cases, prolonged screen time, and genetic predispositions, all contributing to higher rates of vision loss and blindness. Beovu treats retinal diseases by inhibiting VEGF, which reduces fluid leakage and swelling in the retina, thereby improving vision, preventing disease progression, and enhancing patient outcomes for conditions such as wet AMD and diabetic macular edema. For example, according to the National Eye Institute, 2.7 million Americans are currently living with glaucoma, a number projected to rise to 4.3 million by 2030. Additionally, 7.7 million Americans are affected by diabetic retinopathy, with this number expected to increase to 11.3 million by 2030. Therefore, the rising incidence of retinal diseases is driving the growth of the beovu market.

The expanding geriatric population is expected to propel the growth of the beovu market in the coming years. The geriatric population includes individuals aged 65 and older, who often experience various health, social, and functional changes due to aging. This population growth is attributed to factors such as advancements in healthcare, better living conditions, improved nutrition, and increased life expectancy. Beovu (brolucizumab) is particularly beneficial for the elderly, as it helps manage age-related macular degeneration (AMD), a common cause of vision impairment in older adults, by reducing retinal fluid accumulation and stabilizing or improving vision. For instance, in July 2024, according to the UK Parliament's House of Commons Library, there were 12.7 million people aged 65 or older in the UK in 2022, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Consequently, the growing geriatric population is expected to drive growth in the beovu market.

A key trend in the beovu market is the development of innovative therapies, including anti-VEGF injections, to improve treatment outcomes for eye conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Anti-VEGF injections target vascular endothelial growth factor (VEGF), a protein responsible for abnormal blood vessel growth in the eye, thus helping to treat conditions such as wet AMD and DME. For example, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced that the European Commission had approved Beovu (brolucizumab) 6 mg for treating visual impairment due to diabetic macular edema (DME), marking its second indication after the 2020 approval for wet age-related macular degeneration (AMD). This approval offers the potential for fewer injections and better treatment outcomes for DME patients.

The key company operating in the beovu market is Novartis AG.

North America was the largest region in the beovu market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in beovu report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Beovu market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Beovu is a prescription medication used to treat certain eye conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF-A), a protein responsible for the formation of abnormal blood vessels in the eye, which can result in vision problems.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for the beovu market include macular degeneration, diabetic retinopathy, and other related conditions. Macular degeneration is an eye disorder that affects the macula, the central part of the retina, leading to vision loss. It is one of the leading causes of vision impairment in older adults and can progress to a more severe stage, particularly wet age-related macular degeneration (wet AMD), which may require treatments such as Beovu. The available dosage forms include gels, eye solutions, capsules, tablets, eye drops, and ointments. These products are distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies and are used by a wide range of end users, including adults and geriatric patients.

The beovu market consists of sales of beovu vials, pre-filled syringes, multi-dose vials, and single-use injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.